undamentalytics Newsletter
Sign in

Heron Therapeutics, Inc. income statement

In fiscal 2025, Heron Therapeutics, Inc. reported revenue of $155m, up 7.4% on the year before, operating income of −$2.5m (a -1.6% margin) and net income of −$20.2m, or −$0.12 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue131771468986108127144155151
Cost of revenue05286236465565394145
Gross profit126508452405362106114106
Research and development1031391401671751318339171212
Selling and marketing4857659064878368474954
General and administrative2126293842406266535551
Operating income−171−195−184−211−228−218−175−111−12−3−11
Interest expense34312224610—
Income tax0000000000—
Net income−173−197−179−205−227−221−182−111−14−20−34
Diluted EPS−$4.56−$3.65−$2.44−$2.50−$2.50−$2.24−$1.67−$0.80−$0.09−$0.12−$0.20
Diluted shares (average)38m54m73m82m91m98m109m138m152m167m174m
EBITDA−170−193−182−209−225−215−172−108−9−0−9

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HRTX vs NAIIHRTX vs ZVRAAMRN vs HRTXHRTX vs NAGE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Heron Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Heron Therapeutics, Inc.